How to Develop a Patient-Centric R&D Process

Posted by Kristyn Feldman on Wed, Oct 18, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This post is the first in a four-part series examining patient centricity within R&D.

The concept of patient centricity within drug development is far from novel, yet many pharmaceutical companies still struggle to put the patient at the center of their R&D efforts. In a recent article, we wrote about the need for pharmaceutical companies to become true partners in patients’ health. In fact, our research shows that engaging patients from the outset could lead to improved patient recruitment and retention and reduce R&D costs and timelines. Here’s the first step—one of four—that companies can take to start moving toward patient-centric drug development.


>
Read More

Why Pharma Manufacturers Should Partner With Rare Disease Communities

Posted by ZS Editors on Thu, Jul 06, 2017

Patient communities are a valuable asset within the life sciences industry. In the rare disease space, these groups are a vital resource for families battling disease, and serve as much-needed patient representatives to help spur funding, research and scientific advancement. ZS’s Rachael Pius weighs in on why pharmaceutical companies should view these patient communities as partners in clinical development. 


>
Read More